Arbutus completes enrollment in its phase 2a clinical trial combining ab-729 with na therapy and peginterferon alfa-2a in patients with chronic hepatitis b virus infection

Preliminary data from lead-in phase further validates ab-729's capacity to reduce hbsag

ABUS Ratings Summary

ABUS Quant Ranking